Neil Kumar, BridgeBio CEO at BIO22 (J.T. MacMillan Photography for Endpoints News)

July 17, 2023 07:00 AM EDTUpdated 09:41 AM

BridgeBio's ATTR-CM trial odyssey ends with a win, showing positive mortality and hospitalization data

BridgeBio’s long wait for the final results of its Phase III trial of acoramidis is over.

On Monday, the biotech said the 30-month readout of …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bridge­Bio's AT­TR-CM tri­al odyssey ends with a win, show­ing pos­i­tive mor­tal­i­ty and hos­pi­tal­iza­tion da­ta